EUVIMEDEUVIMED entdecken
Multizentrische Studie

Hepatectomy for oligometastatic liver disease in oesophageal adenocarcinoma: The METHEOR study

Boris Cleret de Langavant, Thibault Voron, Marie de Montrichard, Philippe Bachelier, Laurent Sulpice, Nicolas Carrere, Caroline Gronnier, Leonor Benhaim, Ephraim Salamé, Julie Veziant, Clarisse Eveno, Reza Kianmanesh und 7 weitere

European Journal of Surgical Oncology · 2026

DOI: 10.1016/j.ejso.2025.111173 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von Boris Cleret de Langavant und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive and Oncological Surgery, Claude Huriez Hospital, CHU Lille, F-59000, Lille, France. Electronic address: boris.cleretdelangava…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Adenocarcinoma, Liver Neoplasms, Hepatectomy. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Oesophageal cancer is metastatic at diagnosis in 40 % of cases, with liver metastasis (LM) being the second most frequent site. In oligometastatic patients, the survival benefit of ablative therapy over chemotherapy remains unclear. This study aims to evaluate the impact of liver resection on overall and progression-free survival in patients with limited LM from Oesophageal Adenocarcinoma (OA) or Siewert I-II Oeso-Gastric Junction Adenocarcinoma (OGJA). METHODS: This retrospective, multicenter national study included patients treated between 2000 and 2015 in 17 centers. Eligible patients had OA or OGJA, WHO performance status ≤2, and ≤3 resectable, isolated LM. Patients were assigned to two groups: LM ablation with systemic chemotherapy (ablation group) or systemic chemotherapy alone (control group). Exclusion criteria included age >75, extrahepatic disease, non-operable patients, or those who cannot be included in a chemo(radio)therapy-based treatment strategy. RESULTS: Fifty-four patients were included: 31 in the ablation group (57 %) and 23 in the control group (43 %). Both groups were comparable in terms of demographic characteristics, OA, cTNM stage, LM number (p = 0.166) and size (p = 0.622), and timing of metastasis. Postoperative mortality at 90 days was 3.2 %, and severe complications (Clavien-Dindo ≥3) occurred in 12.9 %. Median follow-up was 72 months. Median overall survival and progression-free survival were significantly longer in the ablation group: 36.7 vs. 14.9 months, and 17.7 vs. 9.0 months respectively. LM ablation and pN + status were independently associated with OS. In the ablation group, pN + remained a significant prognostic factor. CONCLUSION: Liver resection for isolated LM in OA and OGJA improved overall and progression-free survival compared to chemotherapy alone. A curative-intent approach is feasible in selected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsAdenocarcinomaLiver NeoplasmsHepatectomyHumansMaleFemaleRetrospective StudiesMiddle AgedAgedSurvival RateProgression-Free Survival

Stichwörter der Autor:innen

Liver metastasesLiver resectionOesophageal adenocarcinomaOligometastatic diseaseSystemic therapy

Autor:innen und Institutionen

  • Department of Digestive and Oncological Surgery, Claude Huriez Hospital, CHU Lille, F-59000, Lille, France. Electronic address: boris.cleretdelangavant@saintluc.uclouvain.be.
  • Dpt of Digestive Surgery, Hôpital Saint Antoine, APHP, Paris, France.
  • Dpt of Digestive Surgery, CHU Nantes, France.
  • Dpt of Digestive Surgery, University Hospital of Strasbourg, France.
  • Dpt of Digestive Surgery, CHU Pontchailloux, Rennes, France.
  • Dpt of Digestive Surgery, CHU Toulouse, France.

Zitieren

APA

Cleret de Langavant, B., Voron, T., de Montrichard, M., Bachelier, P., Sulpice, L., Carrere, N., Gronnier, C., Benhaim, L., Salamé, E., Veziant, J., Eveno, C., Kianmanesh, R., Pessaux, P., Mathonet, M., Facy, O., Lubrano, J., Adam, R., Piessen, G., & FRENCH-FREGAT-ACHBT networks (2026). Hepatectomy for oligometastatic liver disease in oesophageal adenocarcinoma: The METHEOR study. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.111173

Vancouver

Cleret de Langavant B, Voron T, de Montrichard M, Bachelier P, Sulpice L, Carrere N, et al. Hepatectomy for oligometastatic liver disease in oesophageal adenocarcinoma: The METHEOR study. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2025.111173

BibTeX
@article{CleretdeLangavant2026,
  author = {Cleret de Langavant, Boris and Voron, Thibault and de Montrichard, Marie and Bachelier, Philippe and Sulpice, Laurent and Carrere, Nicolas and Gronnier, Caroline and Benhaim, Leonor and Salamé, Ephraim and Veziant, Julie and Eveno, Clarisse and Kianmanesh, Reza and Pessaux, Patrick and Mathonet, Muriel and Facy, Olivier and Lubrano, Jean and Adam, René and Piessen, Guillaume and FRENCH-FREGAT-ACHBT networks, FRENCH-FREGAT-ACHBT networks},
  title = {Hepatectomy for oligometastatic liver disease in oesophageal adenocarcinoma: The METHEOR study},
  journal = {European Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1016/j.ejso.2025.111173}
}
Kostenlos starten →